Predicting in-treatment performance and post-treatment outcomes in methamphetamine users
- PMID: 17493057
- DOI: 10.1111/j.1360-0443.2007.01768.x
Predicting in-treatment performance and post-treatment outcomes in methamphetamine users
Abstract
Aims: This study examines the utility of individual drug use and treatment characteristics for predicting in-treatment performance and post-treatment outcomes over a 1-year period.
Design, setting and participants: Data were collected from 420 adults who participated in the Methamphetamine Treatment Project (MTP), a multi-site study of randomly assigned treatment for methamphetamine dependence. Interviews were conducted at baseline, during treatment and during three follow-up time-points: treatment discharge and at 6 and 12 months following admission.
Measurements: The Addiction Severity Index (ASI); the Craving, Frequency, Intensity and Duration Estimate (CFIDE); and laboratory urinalysis results were used in the current study.
Findings: Analyses addressed both in-treatment performance and post-treatment outcomes. The most consistent finding is that pre-treatment methamphetamine use predicts in-treatment performance and post-treatment outcomes. No one variable predicted all in-treatment performance measures; however, gender, route of administration and pre-treatment methamphetamine use were significant predictors. Similarly, post-treatment outcomes were predicted by a range of variables, although pre-treatment methamphetamine use was significantly associated with each post-treatment outcome.
Conclusions: These findings provide useful empirical information about treatment outcomes for methamphetamine abusers, and highlight the utility of assessing individual and in-treatment characteristics in the development of appropriate treatment plans.
Similar articles
-
A multi-site comparison of psychosocial approaches for the treatment of methamphetamine dependence.Addiction. 2004 Jun;99(6):708-17. doi: 10.1111/j.1360-0443.2004.00707.x. Addiction. 2004. PMID: 15139869 Clinical Trial.
-
A double-blind, placebo-controlled trial of modafinil (200 mg/day) for methamphetamine dependence.Addiction. 2009 Feb;104(2):224-33. doi: 10.1111/j.1360-0443.2008.02437.x. Addiction. 2009. PMID: 19149817 Clinical Trial.
-
Randomized controlled trial of dexamphetamine maintenance for the treatment of methamphetamine dependence.Addiction. 2010 Jan;105(1):146-54. doi: 10.1111/j.1360-0443.2009.02717.x. Epub 2009 Oct 19. Addiction. 2010. PMID: 19839966 Clinical Trial.
-
Technology and innovation in the psychosocial treatment of methamphetamine use, risk and dependence.Drug Alcohol Rev. 2008 May;27(3):318-25. doi: 10.1080/09595230801914768. Drug Alcohol Rev. 2008. PMID: 18368614 Review.
-
Contingency management: an evidence-based component of methamphetamine use disorder treatments.Addiction. 2007 Apr;102 Suppl 1:114-20. doi: 10.1111/j.1360-0443.2006.01774.x. Addiction. 2007. PMID: 17493060 Review.
Cited by
-
Protocol of an open-label safety and feasibility pilot study of ketamine-assisted psychotherapy for methamphetamine use disorder (the KAPPA trial).BMJ Open. 2025 Feb 10;15(2):e092504. doi: 10.1136/bmjopen-2024-092504. BMJ Open. 2025. PMID: 39929500 Free PMC article.
-
Predicting adherence to treatment for methamphetamine dependence from neuropsychological and drug use variables.Drug Alcohol Depend. 2009 Nov 1;105(1-2):48-55. doi: 10.1016/j.drugalcdep.2009.06.008. Epub 2009 Jul 15. Drug Alcohol Depend. 2009. PMID: 19608354 Free PMC article. Clinical Trial.
-
Longer term improvement in neurocognitive functioning and affective distress among methamphetamine users who achieve stable abstinence.J Clin Exp Neuropsychol. 2010 Aug;32(7):704-18. doi: 10.1080/13803390903512637. Epub 2010 Mar 2. J Clin Exp Neuropsychol. 2010. PMID: 20198527 Free PMC article.
-
Predictors of time to relapse in amphetamine-type substance users in the matrix treatment program in Iran: a Cox proportional hazard model application.BMC Psychiatry. 2016 Jul 26;16:265. doi: 10.1186/s12888-016-0973-8. BMC Psychiatry. 2016. PMID: 27455958 Free PMC article.
-
Treatment of rats with an anti-(+)-methamphetamine monoclonal antibody shortens the duration of action of repeated (+)-methamphetamine challenges over a one month period.Vaccine. 2014 Oct 29;32(47):6213-9. doi: 10.1016/j.vaccine.2014.09.025. Epub 2014 Sep 22. Vaccine. 2014. PMID: 25252196 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical